Introduction

Body cavity-based lymphoma -primary effusion lymphoma
ted NHL (AIDS-NHL), clearly a life-threatening disease. The etiology of AIDS-NHL is unknown and is likely to be complex. The malignant B cells in AIDS-NHL are not directly infected with HIV, suggesting that HIV contributes to B cell neoplasia via indirect mechanisms. AIDS-NHL represents a pathologically very heterogenous group of lymphomas ranging from small non-cleaved cell lymphoma to diffuse large cell lymphoma; the latter group includes large non-cleaved cell lymphoma and large cell immunoblastic lymphoma plasmacytoid. 2 Serous effusions are a common complication of lymphomas, mostly as secondary lymphomatous effusions originating from clinically evident solid NHL. Recently, a unique type of primary lymphomatous effusion has been recognized in AIDS patients. 3 Its unique biological, pathological and clinical features led to its identification as an individual nosological entity termed body cavity-based lymphoma (BCBL) or primary effusion lymphoma (PEL) (we generally use here the term PEL henceforth). AIDS-related PEL cases were first reported by Knowles et al 4 in 1989. These lymphoma cells grow exclusively or mainly in pleural, pericardial, or peritoneal cavities as lymphomatous effusions ('liquid lymphomas'), usually without an identifiable tumor mass or lymphoadenopathy throughout their clinical course. 5, 6 The PEL cells have indeterminate immunophenotypes but B cell genotypes with clonal rearrangements of the immunoglobulin genes; positivity for CD138 suggests a mature, preterminal or terminal plasma cell stage of B cell differentiation 2, 5, 7 ( Figure 1 ). The neoplastic cells consistently lack most of the genetic lesions commonly seen in mature B cell malignancies, eg rearrangements of MYC, BCL-2 and BCL-6 as well as mutations of p53. Conversely, mutations of the 5Ј noncoding regions of BCL-6 have been recently suggested to associate with a significant fraction of PEL. 2 PEL occurs predominantly, but not exclusively among HIVinfected patients representing about 3% of all AIDS-NHLs, but less than 0.5% of all non-AIDS-high grade NHLs. 1, 3 The clinical outcome of AIDS-PEL is very poor as median survival ranged from 2 to 6 months; most patients have advanced AIDS and are poor candidates for aggressive chemotherapy. 8, 9 Kaposi's sarcoma-associated herpesvirus -human herpesvirus -8 One of the unique features of PEL cells is their consistent infection with a new type of human virus. Kaposi's sarcomaassociated herpesvirus (KSHV) was first discovered in 1994 by Chang et al 10 in a search for an infectious agent in AIDSassociated Kaposi's sarcoma. They detected unique DNA sequences in Kaposi's sarcoma tumor cells that were closely homologous to minor capsid and tegument protein genes of the gamma-herpesviruses. The sequences appeared to mark a new human herpesvirus that was given the descriptive designation KSHV, and is now often termed HHV-8 (for human herpesvirus-8).
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Herpesviruses have been divided into three major subgroups, termed alpha, beta and gamma, on the basis of their general biological properties in vivo and in vitro. 12 HHV-8 appears to be the first human member of the gamma-2 herpesviruses (genus Rhadinovirus). Its linear double-stranded DNA was estimated to be about 165 kbp. 13 Sequencing of the genomes (130-230 kbp) of several herpesviruses has confirmed these assignments to subgroups and has further allowed the taxonomical classification of newly discovered herpesviruses. Obviously, genomes within the same herpesvirus subgroup show higher amino acid sequence conservation among encoded homologous gene products, and most homologous genes display similar genomic organization. Moreover, in addition to the core of herpesvirus conserved genes (present in every herpesvirus), many genes are unique to each subgroup or to individual herpesviruses. The available HHV-8 sequence data allowed an unambiguous classification of HHV-8 as a gamma-herpesvirus being most closely related to herpesvirus saimiri (HVS). 12 Detection of HHV-8 in lymph nodes and peripheral blood B cells suggests that it is a lymphotropic herpesvirus. Sequence analysis showed partial homology to HVS and Epstein-Barr virus (EBV); both viruses also characteristically replicate in lymphoblastoid cells. 10 HVS, a squirrel monkey virus, causes fulminant T cell lymphomas in primates other than its natural hosts and can also immortalize T cells in vitro. EBV is a human herpesvirus and the closest known relative of HHV-8 in humans. EBV immortalizes B cells in vitro, and is associated with the development of malignant lymphomas including endemic Burkitt's lymphoma, AIDS-NHL, post-transplantation lymphoproliferative disorders and Hodgkin's disease.
14 The EBV nuclear antigens (EBNAs) and latent membrane proteins (LMPs) are thought to be crucial for the maintenance of viral latency and for growth transformation of the host cell by this virus. 13 EBNA-and LMP-homologous genes are entirely missing in HHV-8. Still, since both HVS and EBV appear to be involved in the pathogenesis of malignant lymphomas, it was reckoned that also HHV-8 may quite possibly be a transforming virus leading to the development of lymphoproliferative tumors. 15 There is controversy on the epidemiological infection of normal individuals with HHV-8: examining antibodies against nucleic antigens of HHV-8, some studies detected seroprevalence in less than 1% of normal healthy subjects whereas others found a more widespread positivity (Ͼ20%) in the general population. 13, 16 
CMV, cytomegalovirus; EBNA, Epstein-Barr virus nuclear antigen; EBV, Epstein-Barr virus; HIV, human immunodeficiency virus; HHV, human herpesvirus; HSV, herpes simplex virus; HTLV, human T cell leukemia virus; LMP, latent membrane protein.
Association of HHV-8 infection with malignant diseases
The presence of HHV-8 sequences has been tested in several hundred neoplasms of T and B cell origin in both immunocompetent (non-AIDS) patients and in HIV-seropositive patients. 8 These investigations have conclusively shown the selective association of HHV-8 infection with PEL; all other types of NHL as well as precursor B cell malignancies, plasma cell tumors and T cell neoplasms scored consistently negative. Furthermore, secondary lymphomatous effusions, pyothoraxassociated lymphomas, Hodgkin's disease cases (including cases with the massive involvement of body cavities -both HIV-positive and -negative cases) and reactive lymphoproliferations were consistently HHV-8-negative. 8 Thus, the consistency and selectivity of HHV-8 infection, as well as the relatively high number of HHV-8 DNA copies (20-80 copies per cell) harbored by PEL cells, provides some circumstantial, but still compelling evidence for a pathogenetic role of the virus in the development of PEL. In addition to HHV-8, EBV is also commonly found in PEL cells. While the presence of these two viruses in combination appears to be unique to this type of lymphoma, the detection of HHV-8+ EBV-negative cases questions any synergistic action of HHV-8 and EBV in the pathogenesis of PEL, suggesting that EBV is not an absolute requirement for the manifestation of PEL. Table 2 for details on these cell lines). Note the striking variability in cell size, cell membrane contours, nuclear size, polynuclearity and form, deep cytoplasmic basophilia, and other morphological features. Photographs were taken with a Nikon Labophot photomicroscope using oil immersion and a ×63 objective. details). Thus, while HHV-8 uses homologues of human genes, EBV induces expression of various eukaryotic genes. Apparently, HHV-8 and EBV have developed different strategies to achieve the same goal, namely overcoming cell cycle arrest, apoptosis, and activation of cellular immunity which are typical host responses to viral infection. 13 It has been speculated that these two different strategies might converge to contribute to neoplastic transformation and malignant growth of B cells. 13 In any event, an important co-factor for the establishment of HHV-8-associated tumors appears to be immunodeficiency; this condition may determine the severity and clinical presentation of the disease. HHV-8 appears to play a role in the etiology of some other diseases as well: besides its consistent presence in AIDS-and non-AIDS-PEL and Kaposi's sarcoma, this virus was isolated also from tumor cells of patients with multicentric Castleman's disease and recently in several disorders of terminal B cell differentiation including multiple myeloma, amyloidosis, Waldenströ m's macroglobulinemia and plasmacytoma (here in the bone marrow stromal cells only). 5, 18, 19 The bone marrow dendritic cells of patients with multiple myeloma are supposedly infected with HHV-8. 18, 20 However, these findings were not confirmed by several other investigators. 21, 22 Thus, the role of HHV-8 in multiple myeloma is very controversial; in fact, most groups currently believe that multiple myeloma patients are not infected by HHV-8.
Establishment of continuous cell lines from PEL patients
Over the recent years, a small panel of continuous cell lines has been established from patients with PEL. These cell lines were derived from cell material obtained from malignant pleural effusions, ascitic fluids and peripheral blood. Appropriately, all cell lines contain HHV-8 sequences but either lack or harbor EBV sequences. Previous studies showed that among a spectrum of some 240 human cell lines (comprising solid tumor-derived cell lines and hematopoetic leukemialymphoma cell lines, many of which were established from pleural effusion or ascites material) only PEL cell lines are HHV-8+ 23 (Table 1 ). These PEL cell lines have already played instrumental roles in the analysis of the biology of HHV-8. In the following, the unique clinical, viral, immunophenotypical, cytogenetic, molecular genetic and functional features of these cell lines are presented in detail.
Features of PEL cell lines
Clinical and culture data
The 11 available PEL cell lines were derived from nine males with PEL (cell lines BC-1/HBL-6 and BC-3/KS-1 are independently derived sister cell lines from the same patient, respectively); seven patients were afflicted with AIDS-associated PEL and two men had non-AIDS PEL ( Table 2) . Their ages ranged from 31 to 94 years; 7/9 were HIV-seropositive. Four of the patients had pre-existing Kaposi's sarcoma. The clinical outcome was reported for six of the nine patients. Except for one AIDS-PEL patient (CRO-AP/3) who is alive but with progressive disease and another patient with non-AIDS PEL (BCP-1), the survival after diagnosis of PEL was very short. However, due to end-stage AIDS, the lymphomatous effusions were presumably not the immediate cause of death.
Cell lines were established from malignant pleural effusions (n = 4), ascites (n = 3), an unspecified effusion (n = 1) and peripheral blood (n = 1). All cell lines grow autonomously as single cell suspension cultures in common culture media supplemented with fetal bovine serum (FBS) without any further supplements (eg cytokines) under standard cell culture conditions.
Morphological features
Examples of the morphological features of the PEL cell lines on May-Grü nwald-Giemsa-stained cytospin preparations are shown in Figure 2 .
Viral status
Consistent with their derivation, all PEL cell lines are positive for HHV-8 infection (Table 3, Figure 3) . A relatively high number of HHV-8 DNA copies has been detected in primary PEL cells and PEL cell lines by semi-quantitative polymerase chain reaction and Southern blot analysis: about 40-80 copies/cell for BC-1, about 100 copies for CRO-AP/2, and about 150 copies for BCP-1. 5, 6, 8, 31 It was found that the BC-1 and BC-2 cultures are composed mainly of latently infected proliferating cells with a small proportion of cells which are permissive for virus replication as documented by the appearance of cytopathic changes in these cells, the ability to transmit the virus, and the presence of viral particles containing HHV-8 DNA in culture supernatants. 15 Strong evidence that the infection of PEL cell lines with HHV-8 represents a true latent infection rather than an aberrant or 'dead end' infection came from experiments showing that a switch to productive (lytic) replication was induced in response to appropriate stimuli. 28 Indeed, BCBL-1 (HHV-8+ EBV-neg) exposed to phorbol ester TPA switched to productive (lytic) HHV-8 replication, whereas TPA did not induce this switch in BCBL-2 (HHV-8+ EBV+) raising the possibility that EBV may somehow interfere with HHV-8 induction. 28 Six PEL cell lines are co-infected with EBV, showing a monoclonal pattern of EBV infection (Figure 4b ), whereas the remaining five cell lines are EBV-negative (Table 3, Figure 3 ) suggesting that EBV is not an absolute requirement for the establishment of the cell lines. 8 Furthermore, most EBV+ cell lines display a restricted EBV antigen profile being negative for EBNA-2 and LMP-1 expression, two EBV-encoded transforming antigens. None of the PEL cell lines is positive for other herpesviruses such as CMV, HHV-6, HHV-7, HSV-1 and HSV-2; the cell lines are further negative for the retroviruses HIV, HTLV-1 or HTLV-2 (Table 3) .
Immunoprofiles
Immunophenotyping results of the PEL cell lines are summarized in Table 4 and illustrated in Figure 5 . While most cell lines are CD45
+ (attesting to their hematological origin), the cells exhibit commonly an indeterminate ('null') immunophenotype: none of the cell lines expresses any markers associated with the T cell lineage (CD2, CD3, CD4, CD5, CD7, CD8); the cells are also generally negative for typical B cell antigens such as CD10, CD19, CD20, CD21, CD22, CD40, CD72, CD79a/b and surface immunoglobulin. It is of note that all cell lines examined are positive for CD138 defining the arrest in differentiation at a pre-terminal B cell or plasma cell stage. 2 There is variable expression of activation-associated antigens: HLA-DR (1/3 lines), CD23 (5/7), CD25 (2/2), CD30 (5/8) and CD38 (6/7). All six cell lines tested express epithelial 
Cytogenetic studies
Complete karyotypes are available from nine PEL cell lines 35 ( Table 5 ). The cells harbor numerous clonal chromosome abnormalities within a complex, hyperdiploid karyotype. The cell lines do not carry a t(2;5)(p23:q35), t(3;14)(q27;q32), t(8;14)(q24;q32), t(11;14)(q13;q32) or t(14;18)(q32;q21) which are associated with ALCL, diffuse large-cell lymphoma, Burkitt lymphoma, mantle-cell lymphoma, or follicular lymphoma, respectively. Conversely, PEL cell lines frequently harbor trisomy 7, trisomy 12 and aberrations of chromosomal bands 1q21-q25. 35, 36 The genetic loci implicated by these chromosomal abnormalities are currently not known.
Molecular genetic characteristics
The genotypic features of the PEL cell lines are shown in Table  5 . In all nine cell lines analyzed, Southern blot hybridization revealed clonal rearrangements of the heavy and kappa light immunoglobulin genes, establishing their B cell lineage derivation (Figure 4a) . In contrast to cell lines derived from Burkitt lymphoma, follicular lymphoma or diffuse large cell lymphoma, 37 the PEL cell lines do not have rearrangements of the proto-oncogenes c-MYC (on chromosome 8 band q24), BCL-1 (11q13), BCL-2 (18q21) or BCL-6 (3q27); 35 also the tumor suppressor gene p53 (17p13) was always found in its wildtype form without any point mutations (Table 5) . Interestingly, 7/8 PEL cell lines were found to carry mutations of BCL-6 5Ј non-coding regions, the significance of which remains to be elucidated.
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Functional features
Heterotransplantation: Intraperitoneal (i.p.) or subcutaneous (s.c.) heterotransplantation of BCBL-1 cells into SCID mice elicited signs of ascites and growth of a highly vascularized solid tumor 38 ( Table 6 ). The lesions that developed in SCID mice transplanted with BCBL-1 cells resembled the angiogenic response seen in Castleman's disease. Intravenous or i.p. injection of BCP-1 and HBL-6 into NOD/SCID mice gave rise to effusion tumors similar to those observed in human PEL, including ascites and diffusion of lymphoma cells in various organs; some mice injected s.c. with BCP-1 and HBL-6 developed solid lymphomas, accompanied by marked angiogenesis. 30 Passage of KS-1 cells in triple-immunodeficient BNX mice caused massive ascites. 34 
Viral homologue proteins:
The cell line BC-1 was used for the sequencing of the nearly complete HHV-8 genome allowing definition of the viral genome structure and identification of genes that may play a role in HHV-8-related pathogenesis. 17 Identical sequence patterns have been found for cell line HBL-6.
17 HHV-8 is unique in encoding a number of pro- teins mimicking cell cycle regulatory, receptor and signaling proteins, eg homologues of the cytokine interleukin-6 (IL-6) and the chemokines macrophage inflammatory protein-1 alpha and beta (MIP-1␣/␤), interferon regulatory factor (IRF), the IL-8 receptor (IL-8R), the complement receptor-2 (CR2/CD21), the adhesion molecule NCAM (CD56), the antiapoptotic proto-oncogene Bcl-2, and the cell cycle regulator cyclin D 12, 13, 17, 39 (Table 6 ). The viral IL-6 (vIL-6) has 62% amino acid similarity to the human IL-6 (huIL-6); despite regions of sequence dissimilarity between vIL-6 and huIL-6, the viral interleukin has biological activity in functional bioassays with the mouse plasmacytoma cell line B9 and the human myeloma cell line INA-6 which undergo apoptosis in the absence of IL-6.
12,40,41 TPA or sodium butyrate increased mRNA expression of vIL-6, vIRF and vMIPs in the BC-1, BCP-1 and HBL-6 cell lines which is consistent with expression occurring primarily during virus replication in the lytic phase. 12, 40 Another HHV-8 fragment encodes a putative Gprotein-coupled receptor homologous to huIL-8R; this receptor is constitutively active and demonstrated functional signaling through the phosphoinositide pathway. 42 Molecular mimicry of functional cell cycle regulatory and signaling proteins by HHV-8 is a prominent and unique feature of this virus; this phenomenon is a newly recognized feature of some DNA viruses, particularly herpesviruses and poxviruses. Expression of functional vIL-6 may be an important step in the development of multiple HHV-8-related diseases, potentially contributing to the pathogenesis of HHV-8-related lymphoproliferative disorders such as PEL or the plasma cell variant of Castleman's disease. 16, 40 The oncogenic potential of Bcl-2 overexpression is well established. Recent studies showed that vBcl-2 is functional and prevents early apoptotic cell death in virus-infected cells; TPA also upregulated vBcl-2 expression in BC-1 cells. 43 HHV-8 vBcl-2 may co-operate with other cellular/viral proteins to enhance cellular transformation. Cyclin D proteins are regulatory subunits which activate cellular kinases to phosphorylate checkpoint molecules such as the retinoblastoma (RB) tumor suppressor protein. mRNAs of viral cyclin D homologues were detected in BC-1 and BC-2 cells. 15 The HHV-8-cyclin D protein has been shown to be capable of phosphorylating RB in vitro at authentic sites, including those previously shown to be a hallmark of RB inactivation. 15, 44, 45 While EBV infection leads to the upregulation of several eukaryotic genes, HHV-8 modifies the same signaling and regulation pathways by introducing exogenous genes from its genome. 17 Cellular defense against virus infection commonly involves cell cycle arrest and apoptosis. The HHV-8-encoded vBcl-2, v-cyclin D and vIL-6 are presumably active in inhibiting either apoptosis or cell cycle shutdown. HHV-8 has not formally been shown to be a transforming virus. Nonetheless, dysregulation of cell proliferation control caused by the identified HHV-8-encoded proto-oncogenes and cytokines may directly promote neoplastic expansion of virus-infected cells. 16 Subgenomic HHV-8 fragments were reported to transform NIH 3T3 cells. 17 On the other hand, HHV-8 infection appears to occur in the general population; thus, possibly similar to the EBV and Burkitt's lymphoma scenario, other factors must be required for the development of malignancy. 16, 19 Cytokine production and response to cytokines:
The cell lines BC-1, BC-2 and KS-1 were shown to produce high levels of human IL-6 and IL-10 and to express the IL-6R 46 (Table 6 ). mRNA expression of other cytokines such as basic fibroblast growth factor (bFGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-1␤, IL-8, IL-12, or platelet-derived growth factor (PDGF) was not detected. While interferon (IFN)-␣ and IFN-␥ inhibited clonal growth of the PEL cell lines, other cytokines such as GM-CSF, IL-4, IL-6, IL-8, IL-10 or oncostatin M did not alter it. Human IL-6 (but not vIL-6) antisense oligonucleotides abrogated both IL-6 production and clonal cell growth. The constitutive IL-6 production was suppressed by exposure to TPA. 46 
Colony formation:
As normal B cells do not grow in soft agar, colony formation in soft agar can be used as an indication of malignancy. Both BCP-1 and HBL-6 had high colony-forming efficiency indicating a truly transformed phenotype ( Table 6 ). As BCP-1 is EBV-negative (HBL-6 is EBV +), the presence of EBV is apparently not essential for the colony-forming capacity of PEL cells.
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Synopsis of facts on PEL cell lines
A concise summary of the most relevant features of PEL cell lines is presented in Table 7 . Overall, these cell lines are well characterized and described. The number of available cell lines is still limited. Because they are permanently available model systems, the PEL cell lines represent valuable and indispensable tools for the biological characterization of the primary lymphomatous effusions. Furthermore, these cell lines Table 7 PEL-derived lymphoma cell lines: synopsis of facts provide a continuous source of HHV-8 sequences. Thus, they should be of substantial help in future experiments aimed at determining the transforming capability of the virus and its pathogenetic role in the development of HHV-8-associated diseases.
